BWM
CRL icon

Baystate Wealth Management’s Charles River Laboratories CRL Stock Holding History

Baystate Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed – – 908
2022
Q1 		$0 Hold
1
– – ﹤0.01% 886
2021
Q4 		$0 Hold
1
– – ﹤0.01% 891
2021
Q3 		$0 Hold
1
– – ﹤0.01% 843
2021
Q2 		$0 Hold
1
– – ﹤0.01% 808
2021
Q1 		$0 Buy
+1
New +$278 ﹤0.01% 740

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baystate Wealth Management's CRL Position: Q2 2022 in Review

Baystate Wealth Management sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 1 share.

Baystate Wealth Management first reported a position in CRL in Q1 2021 and held it in 5 quarters. The position peaked at $0 in Q1 2022. 627 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

  • Baystate Wealth Management reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
  • Baystate Wealth Management sold 1 Charles River Laboratories share in Q2 2022.
  • Baystate Wealth Management first reported a position in Charles River Laboratories in Q1 2021 and held it in 5 quarters.
  • Baystate Wealth Management's Charles River Laboratories position peaked at $0 in Q1 2022.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on Baystate Wealth Management's 13F filing for Q2 2022, filed 2 Aug 2022.